Helix Biopharma Corp.
HBP.TO
TSX
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 455.20K | 312.40K | 199.90K | 1.75M | 249.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.09M | 909.20K | 1.17M | 3.84M | 1.34M |
| Operating Income | -1.09M | -909.20K | -1.17M | -3.84M | -1.34M |
| Income Before Tax | -1.09M | -967.60K | -978.50K | -3.85M | -1.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.09M | -967.60K | -978.50K | -3.85M | -1.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.09M | -967.60K | -978.50K | -3.85M | -1.35M |
| EBIT | -1.09M | -909.20K | -1.17M | -3.84M | -1.34M |
| EBITDA | -1.09M | -907.80K | -1.16M | -3.84M | -1.34M |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.07 | -0.03 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.05 | -0.02 |
| EPS Diluted | -0.02 | -0.04 | -0.02 | -0.07 | -0.03 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.05 | -0.02 |
| Average Basic Shares Outstanding | 53.04M | 50.07M | 49.02M | 52.14M | 42.63M |
| Average Diluted Shares Outstanding | 53.04M | 50.07M | 49.02M | 52.14M | 42.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |